Medacta Group (XSWX:MOVE) ROCE %: 11.64% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:MOVE Medacta Group SA XSWX:MOVE
93 GF Score
Price CHF139.80
GF Value CHF168.33
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Medacta Group ROCE %?

Medacta Group XSWX:MOVE +1.30% 93 ROCE % is 11.64% as of Dec. 2025. GuruFocus rates XSWX:MOVE with a GF Score™ of 93/100 and a GF Value™ of CHF168.33 (Modestly Undervalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medacta Group's annualized ROCE % for the quarter that ended in Dec. 2025 was 11.64%.

Medacta Group  (XSWX:MOVE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medacta Group ROCE % Related Terms

Medacta Group ROCE % Historical Data

* Premium members only.

The historical data trend for Medacta Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medacta Group ROCE % Chart

Medacta Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.81 13.48 12.31 16.06 18.28

Medacta Group Semi-Annual Data
Dec15 Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.33 19.34 13.80 25.07 11.64
XSWX:MOVE
93GF Score
Medacta Group SA XSWX:MOVE
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medacta Group ROCE % Calculation

Medacta Group's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=113.938/( ( (739.586 - 147.088) + (856.289 - 202.215) )/ 2 )
=113.938/( (592.498+654.074)/ 2 )
=113.938/623.286
=18.28 %

Medacta Group's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=74.954/( ( (807.352 - 173.367) + (856.289 - 202.215) )/ 2 )
=74.954/( ( 633.985 + 654.074 )/ 2 )
=74.954/644.0295
=11.64 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 11.64% mean?
Medacta Group (XSWX:MOVE) has a ROCE % of 11.64% as of Dec. 2025.
Is Medacta Group's ROCE % too high?
Medacta Group's current ROCE % is 11.64%. The Medical Devices & Instruments industry median ROCE % is 2.26. Medacta Group's value of 11.64% is 415% above this industry median. Overall, Medacta Group has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's ROCE % compare to ABT and SYK?
Medacta Group's ROCE % of 11.64% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.26. Medacta Group's value of 11.64% is 415% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.26, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medacta Group's current ROCE % of 11.64% is 415% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medacta Group's current ROCE % is 11.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Based on GuruFocus' analysis, Medacta Group (XSWX:MOVE) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF168.33, compared to a current price of CHF139.80 — trading 16.9% below its estimated fair value. The current ROCE % is 11.64% and 415% above the Medical Devices & Instruments industry median of 2.26. Medacta Group's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Medacta Group (XSWX:MOVE), the current ROCE % is 11.64% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medacta Group (XSWX:MOVE) Overvalued in 2026?

Based on GuruFocus' analysis, Medacta Group stock appears to be undervalued. The current stock price of CHF139.80 is trading 16.9% below its estimated GF Value™ of CHF168.33. GuruFocus considers Medacta Group to be Modestly Undervalued.

Key valuation signals for XSWX:MOVE:

  • ROCE %: 11.64%
  • GF Value™: CHF168.33 vs. price of CHF139.80 (16.9% below fair value)
  • GF Score™: 93/100 with 2 warning signs
  • Industry Position: 415% above the Medical Devices & Instruments median

No single metric tells the full story. See the XSWX:MOVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medacta Group Business Description

Other Exchanges MOVEz:UK0A05:UK6MD:Germany
Address Strada Regina 34, Castel San Pietro, Ticino, CHE, 6874
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
93GF Score

Get the complete analysis for XSWX:MOVE

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF139.80
Price
CHF168.33
GF Value